Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,701 | 327 | 92.9% |
| Education | $358.18 | 6 | 7.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $497.99 | 54 | $0 (2021) |
| Amgen Inc. | $424.93 | 26 | $0 (2024) |
| Novo Nordisk Inc | $417.67 | 23 | $0 (2024) |
| Allergan, Inc. | $410.44 | 28 | $0 (2020) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $348.03 | 46 | $0 (2023) |
| Astellas Pharma US Inc | $333.12 | 6 | $0 (2024) |
| Lilly USA, LLC | $263.88 | 17 | $0 (2022) |
| ABBVIE INC. | $227.69 | 18 | $0 (2024) |
| Mylan Specialty L.P. | $196.41 | 9 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $184.18 | 10 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $527.16 | 27 | Teva Pharmaceuticals USA, Inc. ($122.31) |
| 2023 | $547.81 | 45 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($143.40) |
| 2022 | $622.11 | 45 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($141.97) |
| 2021 | $823.59 | 50 | AbbVie Inc. ($151.35) |
| 2020 | $642.47 | 49 | Allergan, Inc. ($163.12) |
| 2019 | $575.30 | 40 | Astellas Pharma US Inc ($99.95) |
| 2018 | $716.45 | 45 | Astellas Pharma US Inc ($116.98) |
| 2017 | $604.46 | 32 | Allergan Inc. ($169.07) |
All Payment Transactions
333 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: Cardiology | ||||||
| 11/15/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: Diabetes | ||||||
| 11/11/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: Bone Health | ||||||
| 10/30/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 10/21/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: Central Nervous System | ||||||
| 10/18/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/28/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $24.31 | General |
| Category: Diabetes | ||||||
| 08/26/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $18.51 | General |
| Category: NEUROLOGY | ||||||
| 08/16/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/14/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $14.16 | General |
| Category: Diabetes | ||||||
| 08/10/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: Diabetes | ||||||
| 08/07/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: Central Nervous System | ||||||
| 08/02/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: Bone Health | ||||||
| 07/11/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 05/16/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: Neurology | ||||||
| 05/09/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $13.17 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 04/24/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: Neurology | ||||||
| 04/10/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: Bone Health | ||||||
| 03/29/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $22.39 | General |
| Category: PSYCHIATRY | ||||||
| 03/20/2024 | Radius Health, Inc. | Tymlos (Drug) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: Endocrinology | ||||||
| 03/14/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: Biological | ||||||
| 03/13/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: Neurology | ||||||
| 03/07/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: Diabetes | ||||||
| 02/28/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Inflammation | ||||||
| 02/22/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.21 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 887 | 2,084 | $290,770 | $146,793 |
| 2022 | 13 | 892 | 1,952 | $264,477 | $129,025 |
| 2021 | 13 | 797 | 2,065 | $290,505 | $137,367 |
| 2020 | 16 | 945 | 2,357 | $338,977 | $156,110 |
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 170 | 854 | $128,100 | $55,422 | 43.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 144 | 179 | $40,275 | $25,185 | 62.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 122 | 383 | $45,577 | $23,908 | 52.5% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 43 | 164 | $20,525 | $9,845 | 48.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 64 | 64 | $14,150 | $8,506 | 60.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 105 | 123 | $12,915 | $8,125 | 62.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 30 | 32 | $6,720 | $3,320 | 49.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 34 | $5,916 | $3,199 | 54.1% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 18 | 18 | $3,780 | $2,687 | 71.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 31 | 51 | $3,672 | $2,071 | 56.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 18 | 19 | $3,895 | $1,790 | 45.9% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2023 | 36 | 38 | $1,710 | $1,197 | 70.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 34 | 36 | $1,080 | $1,058 | 98.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 25 | 46 | $1,380 | $439.13 | 31.8% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 21 | 43 | $1,075 | $42.27 | 3.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 207 | 863 | $129,450 | $50,382 | 38.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 111 | 128 | $28,800 | $20,882 | 72.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 131 | 298 | $35,462 | $17,770 | 50.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 135 | 160 | $16,800 | $9,488 | 56.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 65 | 65 | $14,300 | $8,890 | 62.2% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 30 | 150 | $18,750 | $8,190 | 43.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 66 | 69 | $9,317 | $7,440 | 79.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 34 | 70 | $5,040 | $2,433 | 48.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 12 | 12 | $2,088 | $1,064 | 50.9% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2022 | 35 | 35 | $1,575 | $1,049 | 66.6% |
About Dr. Balbir Chahal, M.D
Dr. Balbir Chahal, M.D is a Internal Medicine healthcare provider based in Tomball, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1508850066.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Balbir Chahal, M.D has received a total of $5,059 in payments from pharmaceutical and medical device companies, with $527.16 received in 2024. These payments were reported across 333 transactions from 42 companies. The most common payment nature is "Food and Beverage" ($4,701).
As a Medicare-enrolled provider, Chahal has provided services to 3,521 Medicare beneficiaries, totaling 8,458 services with total Medicare billing of $569,296. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Tomball, TX
- Active Since 09/09/2005
- Last Updated 09/16/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1508850066
Products in Payments
- XIFAXAN (Drug) $359.23
- VRAYLAR (Drug) $272.31
- LONHALA MAGNAIR (Drug) $261.93
- Ozempic (Drug) $188.40
- EVENITY (Biological) $184.60
- ENTRESTO (Drug) $160.18
- Tresiba (Drug) $151.83
- NAMENDA XR (Drug) $143.45
- CHANTIX (Drug) $129.68
- ZENPEP (Drug) $127.12
- Yupelri (Drug) $122.39
- UBRELVY (Drug) $120.89
- XARELTO (Drug) $115.33
- APTIOM (Drug) $112.82
- Prolia (Biological) $105.13
- Vimpat (Drug) $103.98
- EMGALITY (Drug) $97.92
- TRULICITY (Drug) $92.86
- UZEDY (Drug) $91.85
- Tymlos (Biological) $90.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Tomball
Muhammad Irfan, M.d, M.D
Internal Medicine — Payments: $56,330
Shamaila Aslam, Md, MD
Internal Medicine — Payments: $23,675
Muhammad Motiwala, Md, MD
Internal Medicine — Payments: $11,194
Imran Nathani, Md, MD
Internal Medicine — Payments: $10,265
Dr. Mark Le, M.d, M.D
Internal Medicine — Payments: $7,042
Dr. S Janel Beatie, Md, MD
Internal Medicine — Payments: $6,378